Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM. Bartlett NL, et al. Among authors: alland l. Blood. 2020 Nov 19;136(21):2401-2409. doi: 10.1182/blood.2019004701. Blood. 2020. PMID: 32730586 Free PMC article. Clinical Trial.
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. Peethambaram PP, et al. Among authors: alland l. Invest New Drugs. 2015 Apr;33(2):321-31. doi: 10.1007/s10637-014-0171-9. Epub 2014 Nov 8. Invest New Drugs. 2015. PMID: 25380635 Clinical Trial.
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Alland L, Wilding G, Scher HI; Prostate Cancer Clinical Trials Consortium. Rathkopf D, et al. Among authors: alland l. Clin Cancer Res. 2011 Feb 15;17(4):880-7. doi: 10.1158/1078-0432.CCR-10-2955. Epub 2010 Dec 3. Clin Cancer Res. 2011. PMID: 21131556 Free PMC article. Clinical Trial.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Kantarjian H, et al. Among authors: alland l. N Engl J Med. 2006 Jun 15;354(24):2542-51. doi: 10.1056/NEJMoa055104. N Engl J Med. 2006. PMID: 16775235 Free article. Clinical Trial.
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. Keller AM, et al. Among authors: alland l. J Clin Oncol. 2004 Oct 1;22(19):3893-901. doi: 10.1200/JCO.2004.08.157. J Clin Oncol. 2004. PMID: 15459210 Clinical Trial.
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. O'Brien ME, et al. Among authors: alland l. Ann Oncol. 2004 Mar;15(3):440-9. doi: 10.1093/annonc/mdh097. Ann Oncol. 2004. PMID: 14998846 Free article. Clinical Trial.
20 results